Pinney & Scofield
ALLO icon

Pinney & Scofield’s Allogene Therapeutics ALLO Stock Holding History

Pinney & Scofield’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$307 Hold
192
– – ﹤0.01% 241
2026
Q2 		$399 Hold
192
– – ﹤0.01% 229
2026
Q1 		$468 Hold
192
– – ﹤0.01% 239
2025
Q4 		$263 Hold
192
– – ﹤0.01% 210
2025
Q3 		$238 Hold
192
– – ﹤0.01% 216
2025
Q2 		$217 Hold
192
– – ﹤0.01% 219
2025
Q1 		$280 Hold
192
– – ﹤0.01% 216
2024
Q4 		$409 Buy
+192
New +$474 ﹤0.01% 223

Other funds holding ALLO

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Pfizer
Pfizer New York $164M AUM 53.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Pinney & Scofield's ALLO Position: Q3 2026 in Review

Pinney & Scofield held its Allogene Therapeutics (ALLO) position steady in Q3 2026 at 192 shares worth $307. The position accounts for ﹤0.01% of the portfolio, ranked #241.

Pinney & Scofield first reported a position in ALLO in Q4 2024 and has held it in 8 quarters since. The position peaked at $468 in Q1 2026. 141 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.

  • Pinney & Scofield held 192 shares of Allogene Therapeutics worth $307 as of Q3 2026.
  • Pinney & Scofield left its Allogene Therapeutics share count unchanged in Q3 2026.
  • Allogene Therapeutics made up ﹤0.01% of Pinney & Scofield's portfolio in Q3 2026, its #241 holding.
  • Pinney & Scofield first reported a position in Allogene Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • Pinney & Scofield's Allogene Therapeutics position peaked at $468 in Q1 2026.
  • 141 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.

Based on Pinney & Scofield's 13F filing for Q3 2026, filed 12 Nov 2026.